SEC Form 4 · accession 0001209191-18-051897
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jill Marie Broadfoot
Officer — Chief Financial Officer
Period of report
Sep 19, 2018
Accepted (ET)
Sep 21, 2018 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 19, 2018 | P | 26,000 | $0.8122 | A | 52,000 | D | |
| Common StockF2 | Sep 20, 2018 | P | 38,000 | $0.8352 | A | 90,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents weighted average price for the shares. The shares were purchased at price ranging from $0.7989 to $0.8184 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
- F2Represents weighted average price for the shares. The shares were purchased at price ranging from $0.8229 to $0.8480 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.